Literature DB >> 19538114

Rationally designed tularemia vaccines.

Barbara J Mann1, Nicole M Ark.   

Abstract

Tularemia, caused by the Gram-negative bacterium Francisella tularensis, can be contracted by the bite of an arthropod vector or by inhalation. This disease occurs relatively infrequently but can be severe and even life-threatening if untreated. Until recently, there were few laboratories studying this organism; however, concerns over its potential use as a biological weapon have led to renewed attention to F. tularensis research, particularly in the area of vaccine development. Advances in the ability to genetically manipulate F. tularensis, along with knowledge gained from the creation and refinement of attenuated bacterial vaccines for other diseases, continue to foster significant progress in the development of live-attenuated bacterial vaccines, as well as defined antigen and subunit vaccines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19538114      PMCID: PMC2748800          DOI: 10.1586/erv.09.51

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  55 in total

1.  Superoxide dismutase B gene (sodB)-deficient mutants of Francisella tularensis demonstrate hypersensitivity to oxidative stress and attenuated virulence.

Authors:  Chandra Shekhar Bakshi; Meenakshi Malik; Kevin Regan; J Andres Melendez; Dennis W Metzger; Vitaly M Pavlov; Timothy J Sellati
Journal:  J Bacteriol       Date:  2006-09       Impact factor: 3.490

2.  Construction and characterization of an attenuated purine auxotroph in a Francisella tularensis live vaccine strain.

Authors:  Roger Pechous; Jean Celli; Renee Penoske; Stanley F Hayes; Dara W Frank; Thomas C Zahrt
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

3.  Francisella tularensis subsp. tularensis Schu S4 disulfide bond formation protein B, but not an RND-type efflux pump, is required for virulence.

Authors:  Aiping Qin; David W Scott; Barbara J Mann
Journal:  Infect Immun       Date:  2008-05-05       Impact factor: 3.441

4.  Identification of an essential Francisella tularensis subsp. tularensis virulence factor.

Authors:  Aiping Qin; David W Scott; Jennifer A Thompson; Barbara J Mann
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

5.  An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.

Authors:  Chandra Shekhar Bakshi; Meenakshi Malik; Manish Mahawar; Girish S Kirimanjeswara; Karsten R O Hazlett; Lance E Palmer; Martha B Furie; Rajendra Singh; J Andres Melendez; Timothy J Sellati; Dennis W Metzger
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

6.  Native outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis.

Authors:  Jason F Huntley; Patrick G Conley; David A Rasko; Kayla E Hagman; Michael A Apicella; Michael V Norgard
Journal:  Infect Immun       Date:  2008-05-27       Impact factor: 3.441

7.  Identification of Francisella tularensis Himar1-based transposon mutants defective for replication in macrophages.

Authors:  Tamara M Maier; Monika S Casey; Rachel H Becker; Caleb W Dorsey; Elizabeth M Glass; Natalia Maltsev; Thomas C Zahrt; Dara W Frank
Journal:  Infect Immun       Date:  2007-08-06       Impact factor: 3.441

8.  Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases.

Authors:  S H Kim; F Castro; D Gonzalez; P C Maciag; Y Paterson; C Gravekamp
Journal:  Br J Cancer       Date:  2008-08-19       Impact factor: 7.640

9.  A Francisella mutant in lipid A carbohydrate modification elicits protective immunity.

Authors:  Duangjit Kanistanon; Adeline M Hajjar; Mark R Pelletier; Larry A Gallagher; Thomas Kalhorn; Scott A Shaffer; David R Goodlett; Laurence Rohmer; Mitchell J Brittnacher; Shawn J Skerrett; Robert K Ernst
Journal:  PLoS Pathog       Date:  2008-02-08       Impact factor: 6.823

10.  A Francisella tularensis Schu S4 purine auxotroph is highly attenuated in mice but offers limited protection against homologous intranasal challenge.

Authors:  Roger D Pechous; Travis R McCarthy; Nrusingh P Mohapatra; Shilpa Soni; Renee M Penoske; Nita H Salzman; Dara W Frank; John S Gunn; Thomas C Zahrt
Journal:  PLoS One       Date:  2008-06-25       Impact factor: 3.240

View more
  9 in total

1.  Linkage between Anaplasma marginale outer membrane proteins enhances immunogenicity but is not required for protection from challenge.

Authors:  Susan M Noh; Joshua E Turse; Wendy C Brown; Junzo Norimine; Guy H Palmer
Journal:  Clin Vaccine Immunol       Date:  2013-02-27

2.  Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.

Authors:  Katharina Richard; Barbara J Mann; Aiping Qin; Eileen M Barry; Robert K Ernst; Stefanie N Vogel
Journal:  Clin Vaccine Immunol       Date:  2017-03-06

3.  Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain.

Authors:  Katharina Richard; Barbara J Mann; Lenea Stocker; Eileen M Barry; Aiping Qin; Leah E Cole; Matthew T Hurley; Robert K Ernst; Suzanne M Michalek; Daniel C Stein; Philip Deshong; Stefanie N Vogel
Journal:  Clin Vaccine Immunol       Date:  2013-12-18

4.  Protective live oral brucellosis vaccines stimulate Th1 and th17 cell responses.

Authors:  Beata Clapp; Jerod A Skyberg; Xinghong Yang; Theresa Thornburg; Nancy Walters; David W Pascual
Journal:  Infect Immun       Date:  2011-07-18       Impact factor: 3.441

5.  Whole-genome immunoinformatic analysis of F. tularensis: predicted CTL epitopes clustered in hotspots are prone to elicit a T-cell response.

Authors:  Anat Zvi; Shahar Rotem; Erez Bar-Haim; Ofer Cohen; Avigdor Shafferman
Journal:  PLoS One       Date:  2011-05-20       Impact factor: 3.240

6.  Protective immunity against lethal F. tularensis holarctica LVS provided by vaccination with selected novel CD8+ T cell epitopes.

Authors:  Shahar Rotem; Ofer Cohen; Erez Bar-Haim; Liat Bar-On; Sharon Ehrlich; Avigdor Shafferman
Journal:  PLoS One       Date:  2014-01-06       Impact factor: 3.240

7.  Working correlates of protection predict SchuS4-derived-vaccine candidates with improved efficacy against an intracellular bacterium, Francisella tularensis.

Authors:  Roberto De Pascalis; Blake Frey; Helen M Rice; Varunika Bhargava; Terry H Wu; Ross L Peterson; J Wayne Conlan; Anders Sjöstedt; Karen L Elkins
Journal:  NPJ Vaccines       Date:  2022-08-17       Impact factor: 9.399

8.  Clusters versus affinity-based approaches in F. tularensis whole genome search of CTL epitopes.

Authors:  Anat Zvi; Shahar Rotem; Ofer Cohen; Avigdor Shafferman
Journal:  PLoS One       Date:  2012-05-01       Impact factor: 3.240

9.  Deletion Mutants of Francisella Phagosomal Transporters FptA and FptF Are Highly Attenuated for Virulence and Are Protective Against Lethal Intranasal Francisella LVS Challenge in a Murine Model of Respiratory Tularemia.

Authors:  Brandi E Hobbs; Courtney A Matson; Vasileios I Theofilou; Tonya J Webb; Rania H Younis; Eileen M Barry
Journal:  Pathogens       Date:  2021-06-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.